From Bench to Bedside: Review of Gene and Cell-Based Therapies and the Slow Advancement into Phase 3 Clinical Trials, with a Focus on Aastrom’s Ixmyelocel-T

Overview of attention for article published in Stem Cell Reviews and Reports, March 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

blogs: 1 blog

twitter: 1 X user

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 58 Mendeley

Summary Blogs X Dimensions citations

So far, Altmetric has seen 1 blog post.

Aastrom’s critical limb ischemia trial – failure analysis

Cell Trials, 31 Mar 2013

This week, US-based company Aastrom Biosciences announced that they are terminating Phase 3 trial for critical limb ischemia (CLI…